Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?
Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.
Why Is Scholar Rock Holding Stock Climbing Today?
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
The Next ETF Era Begins with Payments - Ad
After Solana and Hedera, another digital-asset ETF has arrived and it targets global money movement.
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities
Bristol Myers will enroll more patients in its Cobenfy Alzheimer's psychosis study after site irregularities, with FDA-supported analysis suggesting encouraging early signals.
What to know about the hepatitis B shot — and why Trump officials are targeting it
NEW YORK (AP) — A federal vaccine advisory committee this week is expected to discuss whether newborns should still get the hepatitis B vaccine — the first shot found to prevent cancer.
Utility Over Hype: ETF Launch Alert - Ad
This ETF isn't about speculation, it's about infrastructure. Seconds-level settlement, low fees, and institutional custody.
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline
RBC upgrades Neumora, citing strong early NLRP3 obesity data and growing pipeline momentum ahead of key 2026 readouts.
AP Lifestyles Digest for week of Dec. 1
Here is the AP Lifestyles Digest for the week of Dec. 1. Note AP's Holiday Gift Guide Digest moved Nov. 12 and is included at the end.
The Smart Money Copper Trade - Ad
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot
Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to streamline Alzheimer's care.
Here's what to know about the federal ban threatening the market for THC-infused drinks and snacks
MINNEAPOLIS (AP) — The production lines at Indeed Brewing moved quickly, the cans filling not with beer, but with THC-infused seltzer. The product, which features the compound that gets cannabis users high, has been a lifeline at Indeed and other craft breweries as in recent years.
They've Done It 20+ Times-Now They've Found a New Memecoin to Watch - Ad
Our analysts have built one of the most reliable track records in the memecoin space by recognizing early momentum signals many traders overlook. Their newest pick shows several of the same early indicators found in past standout performers. Get the details before this story spreads.
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
BiomX works to address FDA device questions as a safety panel supports the BX004 trial, with topline results now expected in Q2 2026.
Trump Says He Doesn't Want To Extend Obamacare Subsidies At All, But Concedes Measures May Be Taken To 'Get Something Else Done'
Trump rejects two-year ACA subsidy extension plan, despite reports of circulated draft framework. White House exploring options to prevent premium hikes.
D.C.'s Quiet Plan for a New Tech Era - Ad
Why did federal agencies receive orders to "clear the runway" for a phenomenon most Americans haven't even heard of yet? And why are billionaires rushing in weeks before January 1? Whitney Tilson decoded the pattern.
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
Novo Nordisk stock falls after disappointing results from Alzheimer's trial. Analysts remain cautious about future growth prospects.
The Miami Project to Cure Paralysis follows science and steady funding to a broader mission
Marc Buoniconti said his father, , explained the secret to the success of their nonprofit and its fundraising efforts simply: “We’re just not good listeners.”
Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly - Ad
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
Here's what's next in the fight to curb climate change, now that talks in Brazil have ended
BELEM, Brazil (AP) — After from U.N. climate talks in the Amazon that fell short of many nations' expectations, experts found some bright spots alongside weighty reasons for worry in the fight against .
Trump Officials Retreat On Social Security Disability Rule After Advocates Sound Alarm
Trump administration drops rule to make it harder for older Americans to qualify for Social Security disability benefits after criticism.
$270,000 Drug. One Competitor. Billion-Dollar Market. - Ad
Phase 3 trial targets recurrent pericarditis with an oral therapy that could disrupt the only approved treatment. And their heart failure program launches in 2026.
Elanco Animal Health Stock Is Undervalued: Analyst
KeyBanc initiates Elanco with an Overweight rating, citing strong Innovation Product growth, margin gains, and a path to lower leverage.
'Rental Family' spotlights real-life Japanese businesses that offer fill-in relatives, friends
TOKYO (AP) — Ryuichi Ichinokawa's life could be right out of the movie “Rental Family” as the founder nearly two decades ago of the Heart Project business in Japan, which he bills as a surrogate attendance service complete with furnishing of extras and family members.
The Repeatable Strategy Behind 20+ Early Memecoin Wins (Revealed) - Ad
Few analysts have been able to consistently spot strong memecoin setups, but our team has developed a repeatable framework that has helped them identify high-momentum plays early. Now they've uncovered a new project showing similar characteristics, and they want you to see the full breakdown yourself.
UN secretary general urges nations at climate talks to be flexible to get results
BELEM, Brazil (AP) — U.N. Secretary-General António Guterres on Thursday called for countries at climate talks in Brazil to compromise and “show willingness and flexibility to deliver results,” even if they fall short of the strongest measures some nations want.
LOCALIZE IT: At least 30 babies in 15 states sickened by growing infant botulism outbreak
EDITORS/NEWS DIRECTORS:
The Next Biggest Bull Run In Over 50 Years - Ad
Gold has hit all-time highs, breaking $4,000 an ounce - but history shows it could be on the verge of its biggest bull run in over half a century... triggered by a likely major event, eerily similar to what happened in the 1970s. (It's NOT inflation or anything you're likely expecting.) Now, a top analyst says you can capture ALL of the upside without touching a risky miner or a boring exchange-traded fund. He sees extraordinary potential gains long term with very little risk.
Be Well: Breaking down fiber, the next food fad
U.S. consumers who have had their fill of finding to everything from cereal to ice cream are about to meet the next big food fad: fiber.
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.
The $43B Big Pharma Story is Starting Over-With a New Player - Ad
Big Pharma once paid $43B for a small biotech with a similar platform. Now, a new company is following that same playbook, leveraging its patented delivery technology to attract partnerships and near-term revenue potential.
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
Novo Nordisk Leans Into Affordability Amid Rising Competition
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.
The Next ETF Era Begins with Payments - Ad
After Solana and Hedera, another digital-asset ETF has arrived and it targets global money movement.
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
WASHINGTON (AP) — The Food and Drug Administration said Friday it will add a new warning and other limitations to a that's been linked to .
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
Utility Over Hype: ETF Launch Alert - Ad
This ETF isn't about speculation, it's about infrastructure. Seconds-level settlement, low fees, and institutional custody.
Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain
Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD drug govorestat.
Workers take on side jobs to combat stagnant salaries and insecurity about employment
NEW YORK (AP) — As workers face , inflation and , some have decided to branch out from their traditional careers. They're taking on side jobs to bring in additional income and provide a backup plan should they , or adding second, third and sometimes fourth jobs — what some call “polyworking” — to the mix.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.